Trial Profile

First in human phase 1 clinical trial of IDE-275

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 4418959 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

13 Feb 2025 According to an IDEAYA Biosciences media release, Data highlighting IDE275's differentiated potential best-in-class profile will be presented with GSK at a medical conference in the first half of 2025.
04 Nov 2024 New trial record
28 Oct 2024 According to IDEAYA Biosciences media release, initiation of the Phase 1 trial for IDE275 is projected in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com